Immuneering Corp (IMRX)

US · Healthcare · Biotechnology

$3.68+9.20%

Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Net profit

$-24.2M

EPS

$-0.37

EPS estimate

$-0.29

EPS came in at -0.37 against a street estimate of -0.29 — a miss of 27.6%.

Market cap

$242.5M

Forward P/E

0.0

P/B

1.44

Book value

$3.38

EPS (TTM)

$-0.92

52-week high

$8.48

52-week low

$3.38

50-day MA

$4.28

200-day MA

$4.81

Beta

0.46

Analysts rate Immuneering Corp a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $17.00.

Insiders

13.83%

Institutions

55.60%

Fund	Stake
FMR Inc	15.00%
BlackRock Inc	6.76%
Sanofi	4.19%
Vanguard Capital Management, LLC	3.53%
T. Rowe Price Associates, Inc.	2.99%
Geode Capital Management, LLC	2.12%
State Street Corp	1.55%
DCF Advisers, LLC	1.22%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immuneering Corp — free to start.

Data updated 2026-11-07.